Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 2019-03-20
• Target enrollment: 0
• Participant gender: All

Summary

The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers. Each subjects will receive three different topical doses of PF 06763809, PF 06763809 vehicle, and two active comparators. These will be applied to six different treatment fields for 18 days. The total duration of participation in the study will be approximately 7 weeks (minimum) to approximately 11 weeks (maximum), including the interval from Screening to the Follow up phone call visit.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Betamethasone; Betamethasone benzoate; Betamethasone sodium phosphate; Betamethasone Valerate; Betamethasone-17,21-dipropionate; Calcipotriene

Criteria

Inclusion Criteria:

• Psoriasis vulgaris in a chronic stable phase and with a plaque area of mild to moderate severity sufficient for six treatment fields located in up to three plaque areas

• Target lesion(s) should be on the trunk or extremities (excluding palms/soles).

Exclusion Criteria:

• History of skin sensitivity to topical prescription or non prescription products such as creams, lotions and cosmetics

• Psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, and pustular psoriasis

• Treatment with any biologics within 3 months prior to Day 1 of the study and during the study